MindWalk Holdings is trading at $0.98, down 5.77%, amid a sharp market-wide selloff in technology shares as investors weigh the possibility that election results could bring tighter AI oversight and slow data-center construction. - The company announced a multi-year antibody-discovery agreement with Teva Australia on November 4; financial terms were not disclosed, and available reporting does not link the news to the decline. - Provided price context shows continued recent weakness, but no company-specific cause was identified for the November 5 drop.